



(11)

EP 2 100 614 B8

(12) **CORRECTED EUROPEAN PATENT SPECIFICATION**

(15) Correction information:
Corrected version no 1 (W1 B1)
Corrections, see
Bibliography INID code(s) 73

(51) Int Cl.:
A61K 38/17 (2006.01) **A61K 39/395** (2006.01)
C07K 16/28 (2006.01) **A61P 35/00** (2006.01)

(48) Corrigendum issued on:
20.11.2013 Bulletin 2013/47

(45) Date of publication and mention
of the grant of the patent:
09.10.2013 Bulletin 2013/41

(21) Application number: **09075103.3**

(22) Date of filing: **19.06.2006**

(54) **Antibody against PDGFR-alpha for use in the treatment of tumours**

Antikörper gegen PDGFR-alpha zur Verwendung bei der Behandlung von Tumoren

Anticorps contre PDGFR-alpha pour l'utilisation dans le traitement de tumeurs

(84) Designated Contracting States:
**AT BE BG CH CY CZ DE DK EE ES FI FR GB GR
HU IE IS IT LI LT LU LV MC NL PL PT RO SE SI
SK TR**

(30) Priority: **17.06.2005 US 691920 P**

(43) Date of publication of application:
16.09.2009 Bulletin 2009/38

(60) Divisional application:
12162951.3 / 2 505 205

(62) Document number(s) of the earlier application(s) in
accordance with Art. 76 EPC:
06785127.9 / 1 909 819

(73) Proprietor: **ImClone LLC**
New York, NY 10016 (US)

(72) Inventors:
• **Loizos, Nick**
Staten Island, NY 10306 (US)
• **Huber, Jim**
Scotch Plains, NJ 07076 (US)

(74) Representative: **Kent, Lindsey Ruth et al**
Eli Lilly and Company Limited
Lilly Research Center
Erl Wood Manor
Sunninghill Road
Windlesham
Surrey GU20 6PH (GB)

(56) References cited:
• **LOIZOS NICK ET AL: "Targeting the platelet-derived growth factor receptor a with a neutralizing human monoclonal antibody inhibits the growth of tumor xenografts: Implications as a potential therapeutic target" MOLECULAR CANCER THERAPEUTICS, AMERICAN ASSOCIATION OF CANCER RESEARCH, US, vol. 4, no. 3, 1 March 2005 (2005-03-01), pages 369-379, XP009104391 ISSN: 1535-7163**
• **SHEN JUQUN ET AL: "Single variable domain-IgG fusion. A novel recombinant approach to Fc domain-containing bispecific antibodies" JOURNAL OF BIOLOGICAL CHEMISTRY, AMERICAN SOCIETY OF BIOLOGICAL CHEMISTS, BIRMINGHAM, US, vol. 281, no. 16, 21 April 2006 (2006-04-21), pages 10706-10714, XP002478591 ISSN: 0021-9258 [retrieved on 2006-02-15]**

Note: Within nine months of the publication of the mention of the grant of the European patent in the European Patent Bulletin, any person may give notice to the European Patent Office of opposition to that patent, in accordance with the Implementing Regulations. Notice of opposition shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).

EP 2 100 614 B8

- DEEVI DHANVANTHRI S ET AL: "Inhibition of human osteosarcoma xenograft growth by anti-Platelet derived growth factor receptor alpha antibody, IMC-3G3, alone and in combination with chemotherapy" PROCEEDINGS OF THE ANNUAL MEETING OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH, NEW YORK, NY, US, vol. 47, 5 April 2006 (2006-04-05), page 877, XP001538531 ISSN: 0197-016X
- BOARD R ET AL: "Platelet-derived growth factor receptor (PDGFR): A target for anticancer therapeutics" DRUG RESISTANCE UPDATES, CHURCHILL LIVINGSTONE, EDINBURGH, GB, vol. 8, no. 1-2, 1 February 2005 (2005-02-01), pages 75-83, XP004919316 ISSN: 1368-7646